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ABSTRACT 
Background: In colorectal cancer (CRC), BRAF mutations influence tumour progression. In 
mismatch repair deficient (dMMR) tumours, BRAF mutations are associated with a good 
prognosis whereas in MMR competent tumours they are detrimental. The differential 
expression of the downstream MAPK pathway members, which are constitutively activated 
in BRAF mutant patients, may account for these differences.  
Methods: Phosphorylation of ERK, p38MAPK and JNK was assessed by 
immunohistochemistry utilising CRC tissue microarrays. A discovery cohort (n=187) and a 
validation cohort (n=801) were analysed for associations with BRAF mutations, 
clinicopathological characteristics and cancer-specific survival (CSS).  
Results: In 801 CRC patients, nuclear ERK phosphorylation (HR 0.65 95% CI 0.48-0.88, 
p=0.004) and the combined nuclear pERK/p-p38 score (HR 0.61 95% CI 0.45-0.82, p=0.001) 
independently associated with CSS and were further associated with increased BRAF 
mutations (p=0.003 and p=0.002). When stratified for BRAF status, only MMR competent 
patients harbouring the mutation and a strong combined nuclear pERK/p-p38 score (HR 0.49 
95% CI 0.27-0.89, p=0.016) demonstrated improved CSS. This improvement in CSS was 
specific to stage III CRC (HR 0.25 95% CI 0.10-0.64, p=0.002).  
Conclusions: MMR competent stage III tumours harbouring BRAF mutations have an 
improved prognosis when strong nuclear phosphorylation of both ERK and p38MAPK is 
present. 
  
Keyword: ERK, p38MAPK, BRAF mutations, colorectal cancer, and prognosis. 
 3 
 
INTRODUCTION 
Colorectal cancer (CRC) is the second most common cause of cancer death in Europe1.  
Although survival has improved, this is predominantly a result of better surgical technique 
and adjuvant/neo-adjuvant therapies. Despite this, 5- year survival remains poor at 60% 
across all stages of disease2. The present TNM-based staging of CRC is suboptimal, given the 
heterogeneity in survival among patients across the same stage of disease.  There is an 
obvious clinical need to identify characteristics pertaining to both the tumour and the host, 
which may not only guide prognosis but also novel adjuvant therapies.    
BRAF V600E mutations are currently being investigated as a predictive biomarker for 
selecting patients for EGFR inhibitor treatment3. BRAF mutations exhibit different 
associations with prognosis dependent on the subset of CRC patients. In sporadic CRC, 
patients with mismatch repair (MMR) deficient (dMMR) tumours harbouring BRAF 
mutations have an improved survival. Conversely, in MMR competent (cMMR) patients, 
BRAF mutations convey a poor prognosis and their prognosis declines further in BRAF 
mutant metastatic disease4. Furthermore, dMMR/BRAF mutant patients have a 5-year 
survival rate of 65% compared to 46% for cMMR/BRAF mutant patients. The reason for this 
difference in survival for BRAF mutant patients is still unclear, but may lie in the expression 
of downstream targets such as extracellular regulated kinase (ERK). 
ERK is part of the mitogen-activated protein kinase (MAPK) family along with two other 
members, p38MAPK and c-Jun-regulated kinase (JNK). All MAPKs are serine-threonine 
kinase activated by dual phosphorylation. The effects of MAPKs on patient survival in 
various cancers are varied5-8, with some studies showing a survival advantage and some a 
detrimental survival effect. Most studies look at the three members in isolation, overlooking 
potential cross talk between the pathways, which may explain the different associations with 
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survival. Therefore, the aim of the present study was to assess the effect of phosphorylation 
of ERK, p38MAPK and JNK alone and in combination on cancer-specific survival in a 
discovery and validation cohort of CRC patients. The study also assessed associations 
between the MAPK pathway, BRAF mutations, MMR status, and clinicopathological factors.  
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METHODS 
Patients 
Discovery cohort patients (n=272) were identified from retrospectively retrieved routine CRC 
resections performed within Glasgow Royal Infirmary between 1997 and 2007. This cohort 
was extended to the validation cohort (n=1030) with the addition of retrospectively identified 
CRC resections performed in the Western Infirmary and Stobhill Hospital, Glasgow in the 
same time period.  Patients who had undergone a potentially curative resection for stage I-III 
CRC and were included within previously constructed tissue microarrays (TMAs) were 
studied. Resections were considered curative based on pre-operative computed tomography 
and intra-operative findings.  Patients who had died within 30 days of surgery were excluded. 
Ethical approval was obtained from the West of Scotland Research Ethics Committee. 
Clinicopathological characteristics 
Tumours were staged using the fifth edition of the AJCC/UICC-TNM staging system9.  
Tumour differentiation was graded in accordance with Royal College of Pathologists10. The 
presence of venous invasion was assessed using Elastica staining. Differentiation, margin 
involvement, peritoneal involvement, and necrosis were taken from pathology reports issued 
following resection. Data on Ki67 was already available for both cohorts using a threshold of 
50%. MMR status was assessed as previously described11. Patients were followed up for at 
least five years and date and cause of death were crosschecked with electronic case records.  
Cancer-specific survival (CSS) was measured from date of surgery until date of death from 
CRC. 
Assessment of inflammatory responses 
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Stromal infiltration was assessed using tumour stroma percentage (TSP) as previously 
described12.  The local inflammatory cell infiltrate was assessed using the Klintrup-Makinen 
(KM) grade13.  The Glasgow microenvironment score (GMS) was calculated as previously 
described14. Tumor-infiltrating lymphocyte (TIL) counts were established from pathology 
reports issued following resection. For systemic inflammation, serum C-reactive protein 
(CRP) and albumin were recorded prospectively and measured within 30 days prior to 
surgery. The pre-operative systemic inflammatory response was defined using the modified 
Glasgow prognostic score (mGPS)15.  
Immunohistochemistry 
BRAF V600E, phosphorylated ERK1/2 (pERK), phosphorylated p38MAPK (p-p38) and 
phosphorylated JNK (pJNK) were assessed via immunohistochemistry (Figure S1) in the 
discovery (n=272) and validation TMAs (n=758). Antibody validation was performed with a 
single band on a western blot and EGF or UV stimulated cell pellet +/- inhibitors. For BRAF 
V600E antibody was also validated using BRAF WT and BRAF V600E mouse colon tissue 
(Figure S2). 
Sections were dewaxed in histoclear then rehydrated using graded alcohols. Antigen retrieval 
for pERK was performed in citrate buffer at 96ºC for 20 minutes or for BRAF V600E, p-p38, 
and pJNK using Tris EDTA buffer pH8 under pressure for 5 minutes. Endogenous peroxidase 
activity was blocked using 3% hydrogen peroxidase. 10% Casein (BRAF V600E), 1.5% 
horse serum (pERK) or 5% horse serum (p-p38/pJNK) was applied as a blocking solution. 
TMA sections were incubated overnight at 4ºC with primary BRAF V600E (1:200, clone 
VE1, Spring Biosciences #E1929), pJNK (Thr183/Tyr185, 1:50, cell signalling #4668) or p-
p38 (Thr180/Tyr182, 1:100, cell signalling #4511) antibody. Primary pERK (Thr202/Tyr204, 
1:200, cell signalling #9101) antibody was incubated for 6 hours at room temperature. 
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Envision (Dako) was used as a secondary antibody before DAB substrate was added for 
colour development. Slides were counterstained with haematoxylin and blued with Scott’s tap 
water before being dehydrated through a series of graded alcohols and histoclear. Cover slips 
were applied using distrene, plasticizer, xylene (DPX).  
Scoring  
Stained TMA sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden 
City, Hertfordshire, UK) at x20 magnification and visualized on Slidepath Digital Image Hub 
(Leica Biosystems, Milton Keynes, UK). Assessment of BRAF V600E, ERK1/2, JNK and 
p38MAPK phosphorylation was performed by a single examiner blinded to clinical data at 
x20 magnification (total magnification x400) using the weighted histoscore. The weighted 
histoscore was calculated as follows: 0x% not stained + 1x% weakly stained + 2x% 
moderately stained + 3x% strongly stained. This gave a range of scores from 0 to 300 with 
cytoplasmic and nuclear staining scored separately. 10% of tumours were co-scored by a co-
investigator and the interclass correlation coefficient calculated to be <0.7 for all proteins. 
Statistical analysis 
Histograms were assessed for each protein and BRAF V600E and pERK histograms 
determined that negative and positive expression was the appropriate threshold. Receiver 
operator characteristic (ROC) curves were employed to identify the optimal threshold for 
low/high expression of p-p38 and pJNK in the discovery cohort and validated using the 
validation cohort, the following thresholds were identified for each protein: 40 for nuclear p-
p38, 10 for cytoplasmic p-p38, 70 for nuclear pJNK, and 145 for cytoplasmic pJNK.  
SPSS (version 22) was used for statistical analysis. By using a two-sided α=0.05 analysis and 
assuming a hazard ratio (HR) of 0.65 and a both high prevalence of 40% for the combined 
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nuclear score, a sample size of >178 patients gave >90% power to detect a survival difference 
between the both low or one high and both high groups. Pearson’s χ2 test assessed 
associations between MAPK members, BRAF mutations, and clinicopathological features. 
Kaplan-Meier curves and log-rank analysis compared CSS. HRs and confidence intervals 
(CI) were calculated from univariate cox regression survival analysis. Multivariate cox 
regression survival analysis using a backward conditional elimination model and a 
significance threshold of p<0.05 was performed to identify independent prognostic 
biomarkers. The study is reported in line with the REMARK guidelines16 and significance 
was set as p<0.05.  
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RESULTS 
For the discovery cohort, a total of 187 patients were studied, and they underwent a 
potentially curative resection for stage I-III CRC and had a valid score for pERK, p-p38 and 
pJNK. The patient characteristics for the discovery cohort are shown in Table S1. In brief, 
64% were 65 or older and 53% were male.  5% had stage I disease, 49% had stage II disease, 
and 46% had stage III disease. 38% had right-sided colon cancer, 30% had left-sided colon 
cancer and 32% had rectal cancer. MMR deficiency was identified in 10% and 20% had the 
BRAF V600E mutation. 31% received adjuvant chemotherapy. The median follow-up for 
patients was 11.6yrs (range 7.3-16.0yrs) with 65 cancer deaths and 45 non-cancer deaths.  
The association between MAPK phosphorylation and CSS within the cytoplasm or nucleus 
was investigated in Table 1. p-p38 and pJNK were not associated with CSS at either cellular 
location. However, phosphorylation of ERK significantly improved CSS within the nucleus 
(HR 0.61 95% CI 0.38-1.00, p=0.048). To assess if analysing the MAPK family in 
combination would provide any additional power, combined prognostic scores were 
established as follows: combined pERK/p-p38 score, combined pERK/pJNK score and 
combined p-p38/pJNK score.  For all combined scores, patients were split into two groups; 
patients with weak activation of both proteins or strong activation of one protein was termed 
both weak or one strong, and patients with strong activation of both proteins termed both 
strong. Only the combined nuclear pERK/p-p38 score provided some additional power to 
improve CSS (HR 0.56 95% CI 0.33-0.95, p=0.030, Table 1). Next, to assess if this increased 
power is relevant, this combined pERK/p-p38 score and pERK alone were taken forward into 
the validation cohort. 
To validate theses findings the cohort was extended to an 801 CRC patient validation cohort. 
CRC patients with a valid score for pERK and p-p38 were included. The characteristics of 
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this cohort are shown in Table S1. In Brief, 68% were 65 or older and 53% were male.  14% 
had stage I disease, 48% had stage II disease, and 38% had stage III disease. 41% had right-
sided colon cancer, 34% had left-sided colon cancer and 24% had rectal cancer. MMR 
deficiency was identified in 16% and 21% had the BRAF V600E mutation.  The median 
follow-up for patients was 12.0yrs (range 7.3-16.0yrs) with 235 cancer deaths and 258 non-
cancer deaths. As this data was similar to that of the discovery cohort it was deemed 
appropriate to validate the findings. 
The validation cohort was assessed for associations with CSS (Table 2); p-p38 did not 
associate with CSS at either cellular location. However, pERK was associated with improved 
CSS within both the nucleus (HR 0.76 95% CI 0.59-0.99, p=0.037) and cytoplasm (HR 0.77 
95% CI 0.60-0.99, p=0.047). When the combined pERK/p-p38 score was assessed, 
associations with improved CSS were strengthened for both nuclear (HR 0.69 95% CI 0.53-
0.90, p=0.005) and cytoplasmic localisation (HR 0.68 95% CI 0.51-0.92, p=0.010). 
pERK and the combined pERK/p-p38 score were then assessed for associations with 
clinicopathological factors as shown in Table 3. Patients with phosphorylation of nuclear 
ERK were more likely to have a BRAF V600E mutation (p=0.003), be MMR competent 
(p=0.010), and have lower CRP levels (p=0.030).  Similarly, patients with phosphorylation of 
cytoplasmic ERK were more likely to have a BRAF V600E mutation (p=0.009) and be MMR 
competent (p=0.032). For the combined nuclear pERK/p-p38 score, patients with a both 
strong score associated with increased BRAF V600E mutations (p=0.002). Whereas a both 
strong score for the combined cytoplasmic pERK/p-p38 score associated with older age 
(p=0.039). No associations with other clinicopathological characteristics or local 
inflammation were seen for any MAPK members. 
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As the combined nuclear pERK/p-p38 score associated with increased BRAF mutations as 
well as pERK alone, firstly associations between nuclear p-p38 and BRAF status were 
assessed as they are normally within divergent MAPK pathways. High nuclear p-p38 did 
associate with increase BRAF mutations (p=0.039, Table S2) suggesting they do interact. 
Next, patients were stratified into BRAF wildtype or BRAF mutant and effects on patients 
CSS assessed (Figure 1).  For phosphorylation of nuclear ERK, CSS was only improved in 
patients with BRAF mutations (HR 0.51 95% CI 0.29-0.90, p=0.018, Figure 1A). This effect 
on CSS was slightly potentiated for the combined nuclear pERK/p-p38 score (HR 0.50 95% 
CI 0.29-0.88, p=0.014, Figure 2B). To further assess BRAF mutant patients, the combined 
nuclear pERK/p-p38 score was assessed for effects pertaining to MMR status (Figure 2). In 
MMR competent patients, a both strong combined nuclear pERK/p-p38 score improved CSS 
(HR 0.49 95% CI 0.27-0.89, p=0.016). Whereas in MMR deficient patients, a both strong 
combined pERK/p-p38 score did not significantly improve patient survival (HR 0.45 95% CI 
0.08-2.16, p=0.285). 
To further investigate the utility of the combined nuclear pERK/p-p38 score within BRAF 
mutant patients, patients were further stratified for TNM-stage. For MMR competent patients 
(Figure S3), only BRAF mutant patients with stage III CRC had improved survival with a 
both strong score (HR 0.25 95% CI 0.10-0.64, p=0.002, Figure S3C). No survival advantage 
was seen for stage I (HR 1.84 95% CI 0.19-17.94, p=0.593, Figure S3A) or stage II patients 
(HR 0.97 95% CI 0.36-2.63, p=0.952, Figure S3B).  No effect of stage was seen in MMR 
deficient patients. 
pERK and the combine pERK/p-p38 score were then taken forwards into multivariate 
analysis with common clinicopathological factors (Table 4). Under multivariate analysis for 
all patients (n=606), TNM-stage (p<0.001), venous invasion (p=0.006), margin involvement 
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(p=0.032), peritoneal involvement (p<0.001), TSP (P=0.030), KM grade (p=0.030), TILs 
(p=0.002), mGPS (p<0.001), nuclear pERK (p=0.004) and the combined nuclear pERK/p-
p38 score (p=0.001) were independent prognostic factors for CSS. When stratified for MMR 
competent BRAF mutant patients (n=136), venous invasion (p=0.003), margin involvement 
(p=0.009), mGPS (p<0.001) and nuclear pERK (p=0.042) remained independently 
prognostic. When further stratified for stage III patients (p=53), margin involvement 
(p=0.029), mGPS (p=0.001) and nuclear pERK (P<0.001) remained independent for CSS.  
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DISCUSSION 
The results of the present study suggest that patients with CRC need strong nuclear 
phosphorylation of both ERK and p38MAPK for a good prognosis. The data shows that this 
survival improvement is enhanced in MMR competent patients with stage III CRC 
harbouring BRAF mutations. However, patients with strong activation of only one protein 
have a poorer survival outcome suggesting that these patients may benefit from a ERK or 
p38MAPK activation. 
ERK has long been associated with malignant transformation in various cancers including 
CRC, with upstream KRAS/BRAF harbouring driver mutations6,8,17. Therefore, it is 
interesting that this improvement in patient survival is specific to BRAF mutant tumours, 
with strong activation of ERK. Previous studies have mainly associated phosphorylation of 
ERK with reduced survival in patients with CRC18,19, however they assessed ERK in 
isolation, and therefore differences in the activation of p38MAPK between cohorts may 
account for the difference in survival effects compared to the present study. p38MAPK is 
thought to suppress cell proliferation in normal cells but can promote proliferation in certain 
cancer cells, and this has been linked to activation levels20. This observation is similar to 
ERK, which has also been shown to adapt its proliferative effects depending on activation 
levels, with strong activation of ERK causing cell cycle arrest and decreased proliferation5. 
Furthermore, p38MAPK has also been shown to suppress ERK activity, which may be 
important in BRAF mutant tumours where ERK is hyper-activated21. In the current study, 
patients with BRAF mutant tumours have a 3-fold increase in nuclear ERK phosphorylation 
compared to BRAF WT tumours (data not shown), supporting the hypothesis that ERK is 
hyper-activated in BRAF mutant patients. Although p38MAPKs is thought to be a poor 
prognostic factor in CRC that promotes cancer cell survival22, most research to date has been 
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restricted to cell lines and mouse models23,24. However, the present tissue data suggests that 
high levels of phosphorylated p38MAPK promote proliferation potentially by inhibiting ERK 
activation. Therefore, in patients with high phosphorylation of both nuclear p38MAPK and 
ERK, p38MAPK may dampen the anti-proliferative effects of ERK to maintain cell 
proliferation. This is in line with previous literature that suggests proliferation measured by 
Ki67 is a good prognostic factor in patients with CRC25,26. However, if only ERK 
phosphorylation is high, then the hyper-activation in BRAF mutant tumours will be 
uncontrolled and start to suppress the cell cycle leading to decreased proliferation and 
reduced patient survival.  
This was observed when assessing the combined nuclear ERK/p38 score in BRAF mutant 
patients. In BRAF mutant patients with strong activation of both ERK and p38MAPK, 
survival is significantly improved.  It is interesting to note that in these patients of the 115 
patients with strong activation of ERK, 95 patients also had strong activation of p38. This 
suggests that dual activation is common in BRAF mutant tumours and accounts for why only 
a slight increase in power is seen between nuclear pERK and the combined pERK/p-p38 
score (figure 1).  This dual activation protects the patient against the hyper-activation of ERK 
allowing the tumor to continue to proliferate, which has been previously shown to convey a 
good prognosis to patients with CRC25.  However, when only one MAPK is highly active or 
both are weak, survival is decreased, which suggests that for a protective influence to ensue, 
high activation levels of both members are required.  When only one member is activated, 
both proliferation and survival rates are lowered to a similar level to that observed for 
patients that have low activation of both.  This suggests that proliferation needs to be driven 
by both members for improved patient prognosis.  This effect is not seen in BRAF WT 
patients, suggesting that only when ERK is hyper-activated can it affect the cell cycle 
inhibiting proliferation, which leads to a worse prognosis for these patients. In BRAF WT 
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patients the levels of ERK activation never reach the threshold to affect the cell cycle, so the 
reduction in proliferation and survival is never produced.  
As BRAF mutations are commonly associated with MMR deficient patients4, we next 
stratified BRAF mutant patient by MMR status. In patients with MMR competent CRC, 
similar results were seen with a both strong nuclear ERK/p38 score conveying a survival 
advantage to the patient, suggesting that this score would be a useful prognostic marker in 
these patients. To confirm the utility of this prognostic marker across all disease stages of 
CRC, we next stratified MMR competent BRAF mutant patients by stage, and found that this 
survival advantage with the nuclear ERK/p38 score was potentiated in patients with stage III 
CRC. Patients with a both weak/one strong score had significantly poorer survival rates. In 
contrast, the survival difference previously observed was lost in stage I/II patients. These 
finding suggest that BRAF mutational analysis should be extended beyond it’s current 
clinical application in metastatic disease to the adjuvant setting to further aid clinicians with 
patient prognosis. 
In conclusion, this is the first study to show a combined survival advantage of ERK and 
p38MAPK in MMR competent BRAF mutant patients with stage III CRC; confirmation in an 
independent cohort is needed. One limitation of this study is that it does not cover metastatic 
disease and therefore further analysis of this combine score in BRAF mutant metastatic 
patients is also warranted. Overall, these results suggest that patients within the adjuvant 
setting with MMR competent Stage III CRC should not only be routinely tested for BRAF 
mutations but should also be further tested for phosphorylation of ERK and p38MAPK to 
fully stratify prognosis. Furthermore, strong expression of only one of these proteins (ERK or 
p38MAPK) could be used as a predictive biomarker for clinical trials in BRAF mutant MMR 
competent CRC patients, establishing the benefit of treatment with an agonist to the other 
 16 
 
member (ERK for p38MAPK agonist and p38MAPK for ERK agonist). This approach would 
assess if this combined MAPK score truly has a prognostic benefit and would help move 
towards a precision medicine approach for patients with CRC. 
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TITLES AND LEGENDS TO FIGURES 
Figure 1. Combined nuclear pERK/p-p38 score stratifies CSS in BRAF mutant CRC 
patients (n=782). Kaplan Meier curves showing associations between (A) pERK or (B) the 
combined nuclear pERK/p-p38 score and CSS in BRAF WT and BRAF mutant patients with 
CRC. 
Figure 2. Combined nuclear pERK/p-p38 score differentially stratifies BRAF mutant 
CRC patient survival in MMR competent and MMR deficient patients (n=165). Kaplan 
Meier curves showing association between the combined nuclear pERK/p-p38 score and CSS 
in BRAF mutant patients with (A) MMR competent or (B) MMR deficient CRC.  


N (%)
10yr CSS 
(SE)
P N (%)
10yr CSS 
(SE)
P
Weak activation 71 (38) 55 (7) 0.048* 69 (37) 55 (7) 0.058
Strong activation 116 (62) 69 (5) 118 (63) 69 (5)
Weak activation 67 (36) 58 (6) 0.237 143 (76) 64 (4) 0.985
Strong activation 120 (64) 67 (5) 44 (24) 61 (8)
Weak activation 86 (46) 62 (6) 0.644 65 (35) 75 (6) 0.055
Strong activation 101 (54) 65 (5) 122 (65) 58 (5)
Both weak or one strong 110 (59) 57 (5) 0.03* 161 (86) 62 (4) 0.214
Both strong 77 (41) 73 (5) 26 (14) 75 (9)
Both weak or one strong 129 (69) 61 (5) 0.217 112 (55) 66 (5) 0.67
Both strong 58 (31) 70 (6) 75 (45) 61 (6)
Both weak or one strong 121 (65) 60 (5) 0.245 156 (83) 64 (4) 0.724
Both strong 66 (35) 69 (6) 31 (17) 64 (9)
Table 1. Phosphorylation of MAPK and cancer-specific survival in discovery cohort patients 
undergoing potentially curative resection of colorectal cancer (n=187)
pERK1/2 
p-p38MAPK 
pJNK 
Combined pERK/p-p38 score 
Combined pERK/pJNK score  
Combined p-p38/pJNK score 
* Significant difference p<0.05
Nuclear Cytoplasmic
N (%) 10yr CSS (SE) P N (%) 10yr CSS (SE) P
 
Weak activation 327 (41) 64 (3) 379 (47) 65 (3) 0.047*
Strong activation 474 (59) 72 (2) 0.037* 422 (53) 72 (2)
 
Weak activation 251 (31) 65 (3) 0.236 380 (47) 66 (3) 0.268
Strong activation 550 (69) 70 (2) 421 (53) 71 (2)
Both weak or one strong 427 (53) 64 (2) 0.005* 536 (67) 65 (2) 0.01*
Both strong 374 (47) 74 (2) 265 (33) 76 (3)
* Significant difference p<0.05
Table 2.   Phosphorylation of MAPK and cancer-specific survival in validation cohort patients undergoing potentially 
curative resection of colorectal cancer (n=801)
Nuclear Cytoplasmic
pERK1/2 
p-p38MAPK 
Combined pERK/p-p38 score
Weak 
(n=327)
Strong 
(n=474) P
Weak 
(n=379)
Strong 
(n=422) P 
Bothweak/one 
strong (n=427)
Both strong 
(n=374) P
Both weak/one 
strong (n=536)
Both strong 
(n=265)
Wild type 265 (84) 352 (75) 0.003* 306 (83) 331 (75) 0.009* 344 (83) 273 (74) 0.002* 416 (80) 201 (76)
Mutant 50 (16) 115 (25) 63 (17) 102 (25) 70 (17) 95 (26) 103 (20) 62 (24)
Competent    529 (80) 405 (86) 0.01* 302 (81) 362 (86) 0.032* 343 (81) 321 (86) 0.065 439 (83) 225 (85)
Deficient 66 (20) 63 (14) 72 (19) 57 (14) 78 (19) 51 (14) 89 (17) 40 (15)
<65 108 (33) 148 (31) 0.591 125 (33) 131 (31) 0.557 140 (33) 116 (31) 0.592 184 (34) 72 (27)
>65 219 (67) 326 (69) 254 (67) 291 (69) 287 (67) 258 (69) 352 (66) 193 (73)
Normal 137 (51) 222 (59) 0.03* 165 (55) 194 (57) 0.595 191 (53) 168 (59) 0.172 256 (56) 103 (54)
High 133 (49) 152 (41) 137 (45) 148 (43) 167 (47) 118 (41) 197 (44) 88 (46)
0 138 (51) 224 (59) 0.069 168 (55) 194 (57) 0.776 192 (53) 170 (59) 0.243 259 (57) 103 (54)
1 89 (33) 97 (26) 95 (31) 91 (26) 112 (31) 74 (26) 135 (29) 51 (27)
2 45 (16) 55 (15) 42 (14) 58 (17) 57 (16) 43 (15) 63 (14) 37 (19)
Absent 242 (76) 368 (79) 0.297 293 (79) 317 (77) 0.527 313 (76) 297 (81) 0.061 398 (76) 212 (82)
Present 75 (24) 95 (21) 77 (21) 93 (23) 101 (24) 69 (19) 123 (24) 47 (18)
Weak 217 (68) 317 (68) 0.966 257 (69) 277 (67) 0.514 276 (66) 258 (70) 0.31 362 (69) 172 (66)
Strong 102 (32) 150 (32) 115 (31) 137 (33) 140 (34) 112 (30) 164 (31) 88 (34)
1 45 (14) 65 (14) 0.567 51 (14) 59 (14) 0.152 61 (14) 49 (13) 0.996 68 (13) 42 (16)
2 152 (46) 234 (49) 171 (45) 215 (51) 201 (47) 185 (50) 252 (47) 134 (51)
3 130 (40) 175 (37) 157 (41) 148 (35) 165 (39) 140 (37) 216 (40) 89 (33)
Absent 218 (67) 318 (67) 0.901 254 (67) 282 (67) 0.954 281 (66) 255 (68) 0.476 353 (66) 183 (69)
Present 109 (33) 156 (33) 125 (33) 140 (33) 146 (34) 119 (32) 183 (34) 82 931)
Low 146 (45) 213 (45) 0.943 169 (45) 190 (46) 0.835 197 (47) 162 (44) 0.412 235 (44) 124 (47)
High 178 (55) 259 (55) 208 (55) 227 (54) 226 (53) 209 (56) 295 (56) 140 (53)
TNM-stage
Venous invasion
Mismatch repair status 
Proliferation Index 
* Significat difference p<0.05
Serum CRP
mGPS
Klintrup-Makinen grade 
Tumour-infiltrating lymphocytes
Age
BRAF status 
Table 3.   Clinicopathological characteristics of validation patients undergoing potentially curative resection of colorectal cancer and cancer-sp
survival (n=801)
Nuclear pERK1/2 Cytoplasmic pERK1/2 Combined nuclear pERK/p38 score Combined cytoplasmic pERK/
P0.228
0.526
0.039*
0.547
0.192
0.078
0.451
0.052
0.364
0.483
-specific 
K/p38 score
Multivariate HR 
(95% CI) P
TNM Stage (I/II/III) 1.87 (1.44-2.45) <0.001
Differentiation (Moderate or well/Poor) 1.10 (0.69-1.75) 0.703
Venous invasion (absent/present) 1.53 (1.13-2.07) 0.006
Margin Invovlement (no/yes) 1.69 (1.05-2.73) 0.032
Peritoneal invovlement (no/yes) 1.79 (1.31-2.45) <0.001
Proliferation Index (Low/High) 0.81 (0.60-1.10) 0.178
Tumour stroma percentage (low/high) 1.43 (1.04-1.99) 0.030
Klintrup-Makinen Grade  (weak/strong) 0.64 (0.48-0.88) 0.030
TILs (absent/present) 0.48 (0.30-0.77) 0.002
mGPS (0/1/2) 1.57 (1.30-1.91) <0.001
Nuclear pERK (low/high) 0.65 (0.48-0.88) 0.004
Combined nuclear pERK/p-p38 score (both low or one high/both high) 0.61 (0.45-0.82) 0.001
TNM Stage (I/II/III) 1.32 (0.74-2.38) 0.351
Venous invasion (absent/present) 2.58 (1.37-4.86) 0.003
Margin Invovlement (no/yes) 4.45 (1.45-13.70) 0.009
Peritoneal invovlement (no/yes) 0.95 (0.48-1.89) 0.887
Klintrup-Makinen Grade  (weak/strong) 0.72 (0.31-1.65) 0.436
TILs (absent/present) 0.42 (0.17-1.02) 0.054
mGPS (0/1/2) 2.66 (1.78-3.98) <0.001
Nuclear pERK (low/high) 0.52 (0.28-0.98) 0.042
Combined nuclear pERK/p-p38 score (both low or one high/both high) 0.58 (0.31-1.06) 0.077
Venous invasion (absent/present) 1.17 (0.43-3.15) 0.762
Margin Invovlement (no/yes) 6.59 (1.21-35.87) 0.029
Klintrup-Makinen Grade  (weak/strong) 0.19 (0.02-1.44) 0.107
TILs (absent/present) 0.21 (0.03-1.69) 0.143
mGPS (0/1/2) 3.01 (1.58-5.73) 0.001
Nuclear pERK (low/high) 0.16 (0.06-0.44) <0.001
Combined nuclear pERK/p-p38 score (both low or one high/both high) 0.34 (0.10-1.19) 0.091
Table 4. Multivariate analysis of MAPK phosphorylation, clinicopathological characteristics and cancer specific 
survival in patients with colorectal cancer (n=606)
All Patients (n=606)
MMR competent BRAF mutant patients (n=136)
* Significant difference
Stage III MMR competent BRAF mutant patients (n=53)
